Kimberly Burlison

Kimberly Burlison is Head of U.S. Market Access at Orchard Therapeutics, where she leads national strategy for payer engagement, reimbursement, and access for the company’s gene therapy portfolio for rare diseases. Her work focuses on partnering with commercial and public payers, advancing value-based agreements, and supporting treatment centers to enable sustainable access to and reimbursement for advanced therapies. With a deep passion for patient-centered care and innovative access solutions, Kim brings a wealth of expertise to the evolving landscape of gene therapy commercialization.